Randhir S Paul, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3700 Kolbe Rd, Chp Regional Medical Center, Lorain, OH 44053 Phone: 440-960-3000 |
Mr. Mark Reid Clutter, PA-C Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3700 Kolbe Rd, Lorain, OH 44053 Phone: 440-960-3000 |
William Glenn Hadcock, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 3700 Kolbe Rd, Chp Regional Medical Center, Lorain, OH 44053 Phone: 440-960-3000 |
Marc Baumgard, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3700 Kolbe Rd, Community Health Partner Of Ohio Critical Care, Lorain, OH 44053 Phone: 440-960-4000 Fax: 440-244-0726 |
Carla Ann O'day, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Chp Regional Medical Center, 3700 Kolbe Rd, Lorain, OH 44053 Phone: 440-960-3000 |
Brian Andrew Romito, D.O. Emergency Medicine - Emergency Medical Services Medicare: Medicare Enrolled Practice Location: 3700 Koble Road, Lorain, OH 44053 Phone: 440-960-3600 |
News Archive
Artemisinin, the "basis of the most effective" malaria treatment recommended by the WHO, took nearly twice as long to clear malaria parasites in patients in western Cambodia than it did in patients in northwestern Thailand, according to a New England Journal of Medicine study, which shows the "drugs are losing their power against the disease in Cambodia," Bloomberg reports (Bennett, 7/30).
Restoration of lost motor function after stroke is typically accomplished after strenuous rehabilitation therapy lasting for over months. However, new research published by a group led by Yukio Nishimura, the project leader of the Neural Prosthesis Project, Tokyo Metropolitan Institute of Medical Science showed that an artificial neural connection (ANC) successfully allowed a new cortical site, previously unassociated with hand movements, to regain control of a paralyzed hand in a matter of minutes.
Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.
The recent report by NHS Cancer Director Professor Mike Richards on the uptake in the NHS of new cancer drugs makes clear that many more people are getting access to effective cancer drugs evaluated by the National Institute for Clinical Excellence.
› Verified 7 days ago